357 related articles for article (PubMed ID: 27079204)
1. Response to bevacizumab after treatment with aflibercept in eyes with neovascular AMD.
Waizel M; Rickmann A; Blanke BR; Wolf K; Kazerounian S; Szurman P
Eur J Ophthalmol; 2016 Aug; 26(5):469-72. PubMed ID: 27079204
[TBL] [Abstract][Full Text] [Related]
2. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
[TBL] [Abstract][Full Text] [Related]
3. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
Ho VY; Yeh S; Olsen TW; Bergstrom CS; Yan J; Cribbs BE; Hubbard GB
Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153
[TBL] [Abstract][Full Text] [Related]
4. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
[TBL] [Abstract][Full Text] [Related]
5. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
[TBL] [Abstract][Full Text] [Related]
6. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice.
Pinheiro-Costa J; Costa JM; Beato JN; Freitas-da-Costa P; Brandão E; Falcão MS; Falcão-Reis F; Carneiro ÂM
Ophthalmologica; 2015; 233(3-4):155-61. PubMed ID: 25896317
[TBL] [Abstract][Full Text] [Related]
7. Aflibercept efficacy in refractory choroidal neovascularization.
Brănişteanu DC; Bîlhă A; Moraru A
Rom J Ophthalmol; 2016; 60(2):96-102. PubMed ID: 29450330
[TBL] [Abstract][Full Text] [Related]
8. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden.
Bro T; Hägg S
Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333
[TBL] [Abstract][Full Text] [Related]
9. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
Cho H; Shah CP; Weber M; Heier JS
Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
[TBL] [Abstract][Full Text] [Related]
10. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
[TBL] [Abstract][Full Text] [Related]
11. Initial utilization of aflibercept in exudative age-related macular degeneration.
Cho H; Weber ML; Shah CP; Heier JS
Eur J Ophthalmol; 2014; 24(4):576-81. PubMed ID: 24706352
[TBL] [Abstract][Full Text] [Related]
12. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients.
Hall LB; Zebardast N; Huang JJ; Adelman RA
J Ocul Pharmacol Ther; 2014 May; 30(4):346-52. PubMed ID: 24552305
[TBL] [Abstract][Full Text] [Related]
13. Experience With Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration.
He L; Silva RA; Ayoub N; Moshfeghi DM; Leng T
Ophthalmic Surg Lasers Imaging Retina; 2015 May; 46(5):542-9. PubMed ID: 26057757
[TBL] [Abstract][Full Text] [Related]
14. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
[TBL] [Abstract][Full Text] [Related]
15. Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration.
Messenger WB; Campbell JP; Faridi A; Shippey L; Bailey ST; Lauer AK; Flaxel CJ; Hwang TS
Br J Ophthalmol; 2014 Sep; 98(9):1205-7. PubMed ID: 24795334
[TBL] [Abstract][Full Text] [Related]
16. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration.
Yonekawa Y; Andreoli C; Miller JB; Loewenstein JI; Sobrin L; Eliott D; Vavvas DG; Miller JW; Kim IK
Am J Ophthalmol; 2013 Jul; 156(1):29-35.e2. PubMed ID: 23668679
[TBL] [Abstract][Full Text] [Related]
17. Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD.
Fassnacht-Riederle H; Becker M; Graf N; Michels S
Graefes Arch Clin Exp Ophthalmol; 2014 Nov; 252(11):1705-9. PubMed ID: 24614949
[TBL] [Abstract][Full Text] [Related]
18. Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD.
Thorell MR; Nunes RP; Chen GW; Doshi RR; Dugar J; George MK; Kim BT; Lowrance MD; Modi D; Nahas Z; Gregori G; Yehoshua Z; Feuer W; Rosenfeld PJ
Ophthalmic Surg Lasers Imaging Retina; 2014; 45(6):526-33. PubMed ID: 25423632
[TBL] [Abstract][Full Text] [Related]
19. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration.
Arcinue CA; Ma F; Barteselli G; Sharpsten L; Gomez ML; Freeman WR
Am J Ophthalmol; 2015 Mar; 159(3):426-36.e2. PubMed ID: 25461263
[TBL] [Abstract][Full Text] [Related]
20. Durability of every-8-week aflibercept maintenance therapy in treatment-experienced neovascular age-related macular degeneration.
Dans KC; Freeman SR; Lin T; Meshi A; Olivas S; Cheng L; Amador-Patarroyo MJ; Freeman WR
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):741-748. PubMed ID: 30806775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
